Intervention Protocol

You have free access to this content

Transjugular intrahepatic portosystemic shunts for hepatorenal syndrome

  1. Andrea Hinojosa-Azaola1,*,
  2. Omar I Salas Nolasco2,
  3. Alejandro G Gonzalez Garay3,
  4. Norberto C Chavez-Tapia4,
  5. Cecilia Solis Galicia5

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 21 MAR 2014

DOI: 10.1002/14651858.CD011039


How to Cite

Hinojosa-Azaola A, Salas Nolasco OI, Gonzalez Garay AG, Chavez-Tapia NC, Solis Galicia C. Transjugular intrahepatic portosystemic shunts for hepatorenal syndrome (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD011039. DOI: 10.1002/14651858.CD011039.

Author Information

  1. 1

    Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Department of Immunology and Rheumatology, México D.F., Distrito Federal, Mexico

  2. 2

    Instituto Nacional de Ciencias Médicas y Nutrición. "Salvador Zubirán", Nephrology and mineral metabolism, Mexico D.F., Distrito Federal, Mexico

  3. 3

    Instituto Nacional de Pediatria, Methodology Research Unit/Neonatology, Mexico City, Distrito Federal, Mexico

  4. 4

    Medica Sur Clinic & Foundation, Department of Gastroenterology, Mexico City, Distrito Federal, Mexico

  5. 5

    Instituto Nacional de Pediatria (Cochrane Mexico), Scientitic Information and Documentation, Mexico City, Distrito Federal, Mexico

*Andrea Hinojosa-Azaola, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga No.15, Col. Sección XVI, Tlalpan, México D.F., Distrito Federal, 14080, Mexico. andreaha@yahoo.com.

Publication History

  1. Publication Status: New
  2. Published Online: 21 MAR 2014

SEARCH

References

Additional references

Alessandria 2002
  • Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. European Journal of Gastroenterology and Hepatology 2002;14:1363-8.
Arroyo 2008
Brensing 2000
  • Brensing KA,  Textor J,  Perz J,  Schiedermaier P,  Raab P,  Strunk H,  et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;4:288-95.
Brok 2008
  • Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61:763-9.
Brok 2009
  • Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98.
CTU 2011
  • Copenhagen Trial Unit. TSA - Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 10 March 2014).
Davenport 2012
  • Davenport A,  Ahmad J,  Al-Khafaji A,  Kellum JA,  Genyk YS,  Nadim MK. Medical management of hepatorenal syndrome. Nephrology, Dialysis, Transplantation 2012;27(4):34-41.
DeMets 1987
DerSimonian 1986
Duvoux 2002
Egger 1997
Egger 2003
  • Egger M, Jüni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technology Assessment 2003;7:1-76.
Gerbes 1998
Gines 2003
Gluud 2008
  • Gluud LL, Thorlund K, Gluud C, Woods L, Harris R, Sterne JA. Correction: reported methodologic quality and discrepancies between large and small randomised trials in meta-analyses. Annals of Internal Medicine 2008;149(3):219.
Gluud 2010
Gluud 2012
Gluud 2014
  • Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2014, Issue 1. Art. No.: LIVER.
Guevara 1998
Guevara 2011
Guyatt 2008
  • Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Resaerch Ed.) 2008;336(7650):924-6.
Harbord 2006
Hasper 2011
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hollis 1999
ICH-GCP 1996
  • International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, Pennsylvania, USA: Barnett International/PAREXEL, 1997.
Ioannou 2003
  • Ioannou GN, Doust J, Rockey DC. Terlipressin for acute oesophageal variceal haemorrhage. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD002147]
Jalan 1996
  • Jalan R,  Redhead DN,  Thomas HW,  Henderson N,  O'Rourke K,  Dillon JF,  et al. Mechanisms of changes in renal handling of sodium following transjugular intrahepatic portal systemic stent-shunt (TIPSS). European Journal of Gastroenterology and Hepatology 1996;8:1111-6.
Jüni 2001
Kjaergard 2001
Kjaergard 2003
Lundh 2012
Macaskill 2001
Moher 1998
  • Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
RevMan 2012 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Royle 2003
  • Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
Rössle 2010
Salerno 2007
  • Salerno F, Cammà C, Enea M, Rössle M, Wong G. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007;133(5):1746.
Savović 2012a
  • Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised, controlled trials. Health Technology Assessment 2012;16(35):1-82.
Savović 2012b
  • Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
Schulz 1995
  • Schulz KF, Chalmers I, Hayes RJ Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
Skagen 2009
  • Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. Journal of Clinical Gastroenterology 2009;43:680-5.
Stadlbauer 2008
  • Stadlbauer V,  Wright GA,  Banaji M,  Mukhopadhya A,  Mookerjee RP,  Moore K,  et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 2008;134:111-9.
Testino 2003
  • Testino G,  Ferro C,  Sumberaz A,  Messa P,  Morelli N,  Guadagni B,  et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepato-Gastroenterology 2003;50:1753-5.
Thorlund 2009
  • Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ionnidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. International Journal of Epidemiology 2009;38(1):276-86.
Thorlund 2010
  • Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
Thorlund 2011
  • Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 10 March 2014).
Wadei 2012
Wetterslev 2008
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
Wetterslev 2009
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
Whitfield 2009
Wong 1995
  • Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular intrahepatic portosystemic stent shunt: effects on haemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Annals of Internal Medicine 1995;122:816-22.
Wong 2004
Wood 2008
  • Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601-5.